BVIZ Vice President from Regensburg reelected in Berlin

In Germany currently over 350 technology and startup centers (TGZ) are active. These have together in the last year provided consultancy to 5,080 successful company startups in their centers. Currently there are a total of 15,660 innovative companies with 91,480 employees in the centers. In both the municipal Regensburg Technology and Startup Centers BioPark and TechBase alone there are currently 130 leaseholders with 1.192 employees here.

The Federal Association BVIZ with its headquarters in Berlin is the lobby association for TGZ, in particular helping young and innovative companies in the difficult initial years with experience, contacts and know-how. The mostly municipal TGZ promote targeted startups at the location and contribute decisively to innovation in Germany. In the last 30 years alone the members of BVIZ have been able to successfully startup almost 50,000 companies and create almost 300,000 new jobs (see image below). For three decades BVIZ has been engaged in improving the startup and innovation structure in Germany and thereby makes an important contribution for the business location in Germany, as the startups of today will become the medium-sized companies of tomorrow or even a part of global companies of the future.

In this year's meeting Dr. Diefenthal was reelected as vice president of the association. He has been active in the association since 2006 and has amongst other matters built up the council of German BioParks there, in which 25 German biotechnology centers with a total of 350,000 m₂ are represented (see map below). In 2009 Dr. Diefenthal elected as speaker of the council and elected to the board in 2011. Since 2014 he has been vice president and on the board of directors of the association. Prior to his time Regensburg he had been able to gain much experience in medium-sized family companies and the startup of his own biotech company. In Regensburg he has successfully built up the BioPark on green pastures and consulted to startups there from the foundation to takeover by a large international concern.

“The exciting exchange with colleagues in the working groups, closed meetings and workshops is an incentive to always learn something new to shape our work on-site better and to run with the times”, summarized Dr. Diefenthal.

“Currently of course we are dealing with the theme of the Corona pandemic. For one with the work safety at the centers, and for another with the many innovative ideas for diagnosis and fight against the Covid19 virus”, said Diefenthal. In the life sciences particularly the framework conditions and demands on the TGZ and startups are just as high. In addition to an expensive and state-of-the-art laboratory infrastructure many biotech companies need to take a deep breath with the financing and implementation of their business ideas.